The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.
Watch
Educating Community Specialists on Evolving Treatment Landscape
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Watch
Future Outlook for Treating Breast and Lung Cancers
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
Watch
Novel Treatment Approaches Under Investigation for HER2+ mBC
November 23rd 2023Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Watch
Reviewing Best Practices in the Surgical Management of Breast Cancer: Key Advances
November 21st 2023In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.
Watch
Future Directions in Gastric Cancer Treatment
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Watch
Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
Watch
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
November 16th 2023Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
Watch
Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer
November 15th 2023Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Watch
Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast Cancer
November 15th 2023Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.
Watch
In this second episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss the traditional surgical approaches that are utilized for patients with breast cancer and some of the challenges faced in those with later-stage disease.
Watch
Dr Haffty on Technical and Biological Advancements in Radiotherapy Within Breast Cancer
November 12th 2023Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.
Watch
Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management
November 10th 2023Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Read More
Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer
November 10th 2023Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
Watch
TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Watch
Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
Watch
French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
November 9th 2023Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.
Watch